The Force Driving IVD Markets: Infectious Disease Testing
ROCKVILLE, Md., Feb. 28, 2018 /PRNewswire/ -- The worldwide infectious disease market is 18.7 billion dollars, nearly a third of the entire in vitro diagnostics market. Growth is expected based on the adaption of new technologies, particularly of molecular and rapid systems; the increased occurrence of infectious disease; and the incidence and awareness of emerging infectious diseases. Other factors include test pricing limits in the United States, slightly improved spending in European hospitals, molecular point-of-care and competing immunoassay systems, better insurance and rising middle classes in emerging nations and the aging of developed nations' populations. This is according to Kalorama Information's latest report: Infectious Disease Diagnostic Testing: World Market Analysis of TB, Flu, HIV, Hepatitis, Strep A, Malaria, HPV, Blood Screening, STDs, ID/AST, HAI, Rapids and Other Test Products.
"Most healthcare systems tend to prioritize infectious disease testing because of the need to target care quickly," said Bruce Carlson, Publisher of Kalorama Information. "Thus infectious disease testing markets tend to be a little less price-sensitive than others. But there are limiters – lots of competition among vendors and among technologies. Markets become mature once they are proved effective."
Kalorama says nearly a third of the revenues earned from clinical testing products are earned from products that detect infectious diseases. Despite this enormous size, the market remains dynamic. It's also a global market: the entire world prioritizes infectious disease in its healthcare provision. Indeed, the demand to detect and counter infectious disease threats has helped launch new technologies such as molecular systems and point of care, PCR-alternative molecular amplification methods, next-generation sequencing (NGS), microarrays and other technologies. Infectious disease testing offers a mix of some mature segments with rapid spikes in market growth in the infectious disease test market occurring with the emergence of new disease threats or acceptance of new routine screening procedures.
"Ours is a large-format market research report but also one that reflects the knowledge we have about infectious disease markets," said Carlson. "Each country market was considered for specific healthcare priorities and available and expected funding in that nation."
Growth leaders included Turkey, India, China and Indonesia, among others.
Kalorama Information's report is available at https://www.kaloramainformation.com/.
About Kalorama Information
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. Reports can be purchased through Kalorama's website and are also available on www.marketresearch.com and www.profound.com.
We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog on our company website: https://www.kaloramainformation.com/.
Press Contact:
Bruce Carlson
212 807 2262
[email protected]
SOURCE Kalorama Information
Share this article